Biogen (NASDAQ:BIIB) Given “Neutral” Rating at Piper Sandler
Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “neutral” rating reiterated by Piper Sandler in a note issued to investors on Thursday,Benzinga reports. They presently have a $115.00 target price on the biotechnology company’s stock. Piper Sandler’s target price indicates a potential downside of 11.98% from the stock’s previous close. Several other equities analysts […]
Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “neutral” rating reiterated by Piper Sandler in a note issued to investors on Thursday,Benzinga reports. They presently have a $115.00 target price on the biotechnology company’s stock. Piper Sandler’s target price indicates a potential downside of 11.98% from the stock’s previous close. Several other equities analysts […]
